Hologic (NASDAQ:HOLX – Get Rating) had its target price increased by equities researchers at Wells Fargo & Company from $75.00 to $80.00 in a research note issued on Tuesday, The Fly reports. Wells Fargo & Company’s price objective would indicate a potential upside of 0.26% from the stock’s current price.
Other equities analysts have also recently issued reports about the stock. Mizuho boosted their price target on shares of Hologic from $75.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, November 1st. Cowen decreased their price objective on Hologic from $88.00 to $86.00 and set an “outperform” rating on the stock in a report on Tuesday, November 1st. SVB Leerink lifted their price objective on Hologic from $78.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday. Evercore ISI boosted their target price on Hologic from $65.00 to $70.00 and gave the stock an “in-line” rating in a research report on Tuesday, November 1st. Finally, Royal Bank of Canada initiated coverage on Hologic in a research note on Tuesday, December 6th. They set a “sector perform” rating and a $75.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $78.33.
Hologic Trading Up 2.5 %
HOLX opened at $79.79 on Tuesday. The stock has a market capitalization of $19.61 billion, a PE ratio of 15.58, a P/E/G ratio of 1.48 and a beta of 1.00. Hologic has a 12-month low of $59.78 and a 12-month high of $81.97. The firm’s fifty day moving average price is $75.01 and its 200 day moving average price is $70.58. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.12 and a quick ratio of 3.45.
Hologic (NASDAQ:HOLX – Get Rating) last issued its quarterly earnings data on Monday, October 31st. The medical equipment provider reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.20. The firm had revenue of $953.30 million for the quarter, compared to the consensus estimate of $861.68 million. Hologic had a net margin of 26.77% and a return on equity of 31.85%. Hologic’s quarterly revenue was down 27.6% compared to the same quarter last year. During the same period last year, the firm posted $1.61 EPS. As a group, research analysts expect that Hologic will post 3.46 EPS for the current fiscal year.
Insider Buying and Selling at Hologic
In related news, CFO Karleen Marie Oberton sold 14,545 shares of the company’s stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $72.50, for a total value of $1,054,512.50. Following the sale, the chief financial officer now directly owns 126,811 shares of the company’s stock, valued at $9,193,797.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, General Counsel John M. Griffin sold 26,902 shares of Hologic stock in a transaction on Monday, November 14th. The stock was sold at an average price of $76.12, for a total value of $2,047,780.24. Following the transaction, the general counsel now directly owns 168,944 shares in the company, valued at approximately $12,860,017.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Karleen Marie Oberton sold 14,545 shares of the business’s stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $72.50, for a total value of $1,054,512.50. Following the transaction, the chief financial officer now owns 126,811 shares in the company, valued at $9,193,797.50. The disclosure for this sale can be found here. Corporate insiders own 1.54% of the company’s stock.
Hedge Funds Weigh In On Hologic
A number of hedge funds have recently bought and sold shares of HOLX. Yousif Capital Management LLC increased its holdings in shares of Hologic by 33.9% in the fourth quarter. Yousif Capital Management LLC now owns 64,190 shares of the medical equipment provider’s stock valued at $4,802,000 after purchasing an additional 16,256 shares during the last quarter. Wedmont Private Capital acquired a new stake in shares of Hologic during the 4th quarter worth about $277,000. General Partner Inc. acquired a new position in Hologic during the fourth quarter worth approximately $49,000. Continental Investors Services Inc. purchased a new position in shares of Hologic in the 3rd quarter valued at approximately $869,000. Finally, American Trust grew its stake in shares of Hologic by 5.1% in the 3rd quarter. American Trust now owns 4,864 shares of the medical equipment provider’s stock valued at $314,000 after purchasing an additional 238 shares during the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women’s health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.